**LEARNER NOTIFICATION**

**Society of Cardiovascular Anesthesiologists**

**Activity Title:**  2023 Annual Meeting and Workshops

**Date:** May 6-9, 2023

**Acknowledgement of Monetary Commercial Support**

The following company provided monetary support for this CME educational activity in the form of an unrestricted educational grant: **None**

**Acknowledgement of In-Kind Support**

The following companies provided in-kind support for this CME educational activity: **GE Healthcare, Philips Healthcare, Mindray, LivaNova, Getinge, Abiomed, CAE**

**Accreditation Statement**

The Society of Cardiovascular Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Society of Cardiovascular Anesthesiologists designates this live activity for a maximum of 36.25 *AMA PRA Category 1 Credits*™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification in Anesthesiology™ program and MOCA® are registered trademarks of The American Board of Anesthesiology®.

**CREDIT DESIGNATION**

This activity offers up to 36.25 CME credits, of which 11 credits contribute the patient safety CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

**Description:**

Annual societal meeting that presents education and research for cardiovascular anesthesiologists.

**Educational Information**

**Physician Practice Gap:**

A gap in physician performance in echocardiography and knowledge base in cardiothoracic anesthesiology will be addressed. This conference addresses several current gaps in cardiac anesthesiology: communication and teamwork in the cardiac surgical workplace, professional advancement of anesthesiologists into leadership positions and in academia, advanced echocardiography and point of care ultrasound technique, and up to date clinical information and best practices in cardiothoracic anesthesiology practice.

**Needs that Underlie the Gap**

Interpret and extrapolate current knowledge, evidence, and guidelines into anesthetic decision making for perioperative management of patients undergoing cardiac, thoracic, or vascular surgical procedures.

**DESIGNED to Change/Outcome**: Following this activity, learners will develop competence by increasing their knowledge through a combination of hands-on learning, case-based presentations, and online lectures. Knowledge will be assessed with a pre-test and post-test.

The physicians in attendance will be able to deliver a higher quality of care in cardiothoracic anesthesiology and cardiac surgical procedures by reviewing evidence-based material that has been identified as a professional practice gap, by attending workshops to improve hands-on delivery of cardiac anesthesia care, and to improve health care delivery in the cardiothoracic surgical space. Teaching modalities will include panel discussions, hands-on workshops, and problem-based learning discussions.

**Educational Objectives**

*After completing this activity, the participant should be better able to:*

* describe the latest advances in perioperative cardiovascular medicine.
* identify current trends in clinical and bench research pertinent to cardiovascular medicine and incorporate this knowledge into understanding of the science of cardiothoracic and vascular anesthesia.
* evaluate new therapeutic techniques and diagnostic/interventional procedures in cardiothoracic and vascular anesthesiology.
* discuss quality of care issues, including applicable metrics, as mechanisms to assist with quality improvement at the learner’s institution and address value-based purchasing programs initiated by the federal government.
* discuss advances in clinical echocardiography and point-of-care ultrasound and how to use them to improve outcomes in cardiac surgical patients.
* acquire skills necessary for career progression in cardiovascular and thoracic anesthesia.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available.

**Contact Information**

If you have questions regarding your CME certificate, please contact Kerim Oz, kerim@veritasamc.com.

**Disclosure of Financial Relationships**

As an accredited provider of the ACCME, SCA adheres to all [ACCME Standards for Integrity and Independence in Accredited Continuing Education](https://accme.org/sites/default/files/2022-06/884_20220623_Standards%20for%20Integrity%20and%20Independence%20in%20Accredited%20Continuing%20Education.pdf). SCA collects disclosures from all individuals who have the ability to control the content of CME activities. The following individuals in control of content development for this activity have indicated that they do have financial relationships with ACCME defined ineligible companies within the past 24 months. All financial relationships have been mitigated. All others in control of content not listed below have indicated that they have no financial relationships to disclose.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Last Name** | **First Name**  | **Disclosures (s)** | **Role**  | **Method of Mitigation**  |
| Abernathy | James | Becton Dickinson, Advisory Board, Intelliport - Consulting Fees (Ongoing) | Speaker, Moderator, Course Director, Planning Committee Member, Faculty Presenter, Program Planner | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Bhatt | Himani | Neochord, LLC – Clinical Consultant | Planning Committee Member, Faculty Presenter | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Boncyk | Tina | Sedana Medical - Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Bottiger | Brandi | Csl Behring - Consulting Fees (Ongoing) | Speaker, Moderator, Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Brodt | Jessica | Cyban Pty Ltd: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing) | Speaker, Moderator | The Education Committee has reviewed this presentation and determined that the declared financial relationships are not related to the content of this presentation.  |
| Brown IV | Charles | Medtronic: Other Financial or Material Support (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Cardonell | Bradford | Edwards Lifesciences: Honoraria (Ongoing) | Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Champeau | Michael | Alcon - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022); Eli Lily - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022); Halyard Health Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022); Merck - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022); Novartis - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022); Organon - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022); Pfizer - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022); Roche - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022); RomTech-Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Spiro Robotics - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Viatris - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated, September 23, 2022) | Speaker | The Education Committee has reviewed this presentation and determined that the declared financial relationships are not related to the content of this presentation. |
| Coker | Bradley | American Society of Anesthesiologist - Consulting Fees (Ongoing) | Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Domino | Karen | Edwards Lifesciences - Other Financial or Material Support (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Drzymalski | Dan | Fresenius Kabi - Honoraria (Terminated, February 10, 2021) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Essandoh | Michael | Boston ScientificS4 Medical - Consulting Fees (Ongoing), Consulting Fees (Ongoing) | Speaker, Moderator, Planning Committee Member, Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Fleming | Neal | Acacia Pharma -Other Financial or Material Support; Edwards Life Sciences - Other Financial or Material Support; Haisco Pharmaceuticals - Other Financial or Material Support, Masimo, Inc. - Other Financial or Material Support, Rostrum Medical Innovations - Other Financial or Material Support, Tsumera Pharmaceuticals - Other Financial or Material Support | Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Ghadimi | Kamrouz | Octapharma - Other Financial or Material Support (Ongoing) | Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Glas | Kathryn | Chiesi - Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Grocott | Hilary | Anesthesia Labs Inc., - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Edwards Life Sciences - Honoraria (Ongoing) | Speaker, Moderator | The Education Committee has reviewed this presentation and determined that the declared financial relationships are not related to the content of this presentation. |
| Hensley | Nadia | Octapharma, USA - Consulting Fees (Ongoing), Royalties (Ongoing) | Speaker, Moderator, Planning Committee Member, Faculty Presenter, Program Planner | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Huang | Jiapeng | GE Healthcare - Consulting Fees (Ongoing); Gilead Sciences - Other Financial or Material Support (Ongoing); Potreo Medical - Other Financial or Material Support (Ongoing) | Speaker, Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Joshi | Ravi | RomTech Inc. - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing) | Speaker, Moderator, Reviewer | The Education Committee has reviewed this presentation and determined that the declared financial relationships are not related to the content of this presentation. |
| Keeyapaj | Worasak | Cerus - Honoraria (Ongoing), Other Financial or Material Support (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Kunst | Gudrun | BioMerieux - Consulting Fees (Terminated, January 24, 2023); Edwards Life Sciences - Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Lester | Laeben | MDAirSupport - Other Financial or Material Support (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Lewis | Choy | Edwards Life Sciences - Consulting Fees (Ongoing); La Jolla Pharmaceutical Company - Other Financial or Material Support (Ongoing) | Speaker, Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Martin | Archer | Scientific Advisory Board - Attgeno AB - Consulting Fees (Ongoing) | Reviewer, Planning Committee Member | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Mathis | Michael | National Institutes of Health - Salary (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Mazer | David | BioAge - Consulting Fees (Ongoing); Cerus - Honoraria (Ongoing); PhaseBio - Consulting Fees (Terminated, December 31, 2022); Takeda - Honoraria (Terminated, July 19, 2022) | Speaker, Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Mazzeffi | Michael | Cellphire - Other Financial or Material Support (Terminated); HemoSonics - Consulting Fees (Terminated),Octapharma - Consulting Fees (Terminated) | Speaker, Moderator, Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| McCartney | Sharon | Humacyte - Consulting Fees (Ongoing) | Speaker, Moderator, Planning Committee Member, Faculty Presenter | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Methangkool | Emily | Edwards Lifesciences - Consulting Fees (Ongoing); UpToDate - Honoraria (Ongoing) | Moderator, Reviewer, Planning Committee Member | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Mittnacht | Alex | Cardio Ring - Consulting Fees (Ongoing); Manual Surgical Sciences - Consulting Fees (Ongoing), Manual Surgical Sciences - Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing) | Speaker, Moderator | The Education Committee has reviewed this presentation and determined that the declared financial relationships are not related to the content of this presentation. |
| Nelson | Mark | Daxor Corp - Consulting Fees (Ongoing) | Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Parwani | Purvi | Astrazeneca - Consulting Fees (Ongoing); Medtronic - Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Raphael | Jacob | Octapharma USA - Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Sakai | Tetsuro | Haemonetics Inc - Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Shaw | Andrew | AM Pharma - Consulting Fees (Ongoing); Edwards Life Sciences - Consulting Fees (Ongoing); Novartis - Consulting Fees (Ongoing),Renibus - Consulting Fees (Ongoing); Retia - Consulting Fees (Ongoing) | Speaker, Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Shernan | Stanton | e-echocardiography.com - Other Financial or Material Support (Ongoing); Philips - Other Financial or Material Support (Ongoing) | Speaker, Moderator, Reviewer | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Shook | Douglas | Baylis - Consulting Fees (Terminated); Baylis- Honoraria (Terminated); Edwards Life Sciences - Consulting Fees (Ongoing); Edwards Life Sciences -Honoraria (Ongoing);UpToDate-Honoraria (Ongoing) | Speaker, Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Shore-Lesserson | Linda | Werfen - Honoraria (Terminated, November 12, 2022) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Spence | Jessica | AOP Pharma - Other Financial or Material Support (Ongoing) | Speaker, Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Swaminathan | Madhav | Alexion - Consulting Fees (Terminated); US2.AI - Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Tuck | Benjamin | CardiacAnesthesiaBoards LLC - Consulting Fees (Ongoing) | Planning Committee Member, Faculty Presenter | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Vegas | Annette | Abbott Medical- Honoraria (Terminated, December 31, 2022); Springer Publishing- Royalties (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

**How to Get Your CME Certificate**

1. Go to <https://www.surveymagnet.com/Magnet3/login.asp?EventKey=DWIDCGLY> (link will become active at the conclusion of the meeting)

2. Login and evaluate the meeting.

3. Print all pages of your certificate for your records.